(Reuters) -Ionis Pharmaceuticals said on Monday its experimental brain disorder drug met the main goal in an early-to-late-stage study.
The drug, zilganersen, helped stabilize patients’ ability to walk, based on a test that measures how fast someone can walk 10 meters. The difference between those who received zilganersen and those who didn’t was statistically significant, the company said.
The study tested 54 patients with Alexander disease, a rare genetic disorder that damages brain cells and causes problems with movement, speech, and swallowing, often starting in early childhood.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Shailesh Kuber and Mrigank Dhaniwala)
Comments